Barclays
PRLD icon

Barclays’s Prelude Therapeutics PRLD Stock Holding History

Barclays’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$75.7K Buy
19,363
+4,834
+33% +$23.7K ﹤0.01% 4424
2026
Q2 		$77.4K Buy
14,529
+5,929
+69% +$25.8K ﹤0.01% 4160
2026
Q1 		$29.4K Sell
8,600
-2
-0% -$5 ﹤0.01% 4488
2025
Q4 		$24.9K Sell
8,602
-110
-1% -$186 ﹤0.01% 4845
2025
Q3 		$12.5K Buy
8,712
+110
+1% +$110 ﹤0.01% 5002
2025
Q2 		$6.96K Sell
8,602
-14,543
-63% -$12.6K ﹤0.01% 4942
2025
Q1 		$17.8K Sell
23,145
-6,628
-22% -$6.18K ﹤0.01% 4801
2024
Q4 		$38K Buy
29,773
+2,608
+10% +$3.46K ﹤0.01% 4815
2024
Q3 		$56.2K Buy
27,165
+12,564
+86% +$58.2K ﹤0.01% 4719
2024
Q2 		$55.6K Sell
14,601
-5,786
-28% -$23.5K ﹤0.01% 4166
2024
Q1 		$96.6K Sell
20,387
-10,139
-33% -$39.4K ﹤0.01% 4448
2023
Q4 		$130K Buy
30,526
+17,210
+129% +$52.4K ﹤0.01% 4563
2023
Q3 		$41.1K Buy
13,316
+7,264
+120% +$27.3K ﹤0.01% 3949
2023
Q2 		$27.2K Sell
6,052
-4,270
-41% -$25.5K ﹤0.01% 4068
2023
Q1 		$58.8K Sell
10,322
-80,502
-89% -$491K ﹤0.01% 4392
2022
Q4 		$549K Buy
90,824
+85,656
+1,657% +$549K ﹤0.01% 3254
2022
Q3 		$34K Buy
5,168
+1,108
+27% +$7.47K ﹤0.01% 3898
2022
Q2 		$21K Sell
4,060
-1,817
-31% -$9.25K ﹤0.01% 4381
2022
Q1 		$40K Buy
+5,877
New +$53.8K ﹤0.01% 4202

Other funds holding PRLD

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Barclays's PRLD Position: Q3 2026 in Review

Barclays increased its Prelude Therapeutics (PRLD) stake by 33% in Q3 2026, buying an estimated $23.7K and bringing the position to 19,363 shares worth $75.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4424.

Barclays first reported a position in PRLD in Q1 2022 and has held it in 19 quarters since. The position peaked at $549K in Q4 2022. 28 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

  • Barclays held 19,363 shares of Prelude Therapeutics worth $75.7K as of Q3 2026.
  • Barclays bought 4,834 Prelude Therapeutics shares in Q3 2026, an estimated $23.7K.
  • Prelude Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4424 holding.
  • Barclays first reported a position in Prelude Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Prelude Therapeutics position peaked at $549K in Q4 2022.
  • 28 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.